Search research articles
Contact Us
Filters
Showing results (1-10 of 33) with videos related to
Page
of 4
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics
|
November 6, 2017
Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection
Yasunori Aoki, Daniel Röshammar, Bengt Hamrén, et al.
British Journal of Clinical Pharmacology
|
July 25, 2016
Application of the integrated glucose-insulin model for cross-study characterization of T2DM patients on metformin background treatment
Joanna Parkinson, Bengt Hamrén, Maria C Kjellsson, et al.
British Journal of Clinical Pharmacology
|
February 26, 2008
Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion
Bengt Hamrén, Hans Ericsson, Ola Samuelsson, et al.
Journal of Clinical Pharmacology
|
May 21, 2010
A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes
Jakob Ribbing, Bengt Hamrén, Maria K Svensson, et al.
Clinical Pharmacokinetics
|
April 12, 2019
Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease
Carl Amilon, Mohammad Niazi, Anders Berggren, et al.
Pharmaceutical Research
|
August 2, 2020
Dose-Response Mixed Models for Repeated Measures - a New Method for Assessment of Dose-Response
Gustaf J Wellhagen, Bengt Hamrén, Maria C Kjellsson, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
February 1, 2017
Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
Daniel Röshammar, Martin Bergstrand, Tomas Andersson, et al.
Journal of Clinical Pharmacology
|
November 3, 2011
Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus
Bengt Hamrén, K Peter Ohman, Maria K Svensson, et al.
Journal of Clinical Pharmacology
|
November 19, 2016
Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction
Daniel Röshammar, Joakim Nyberg, Tomas Andersson, et al.
Journal of Clinical Pharmacology
|
October 4, 2014
Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA)
John Maringwa, Matts Kågedal, Ulrika Wählby Hamrén, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 33) with videos related to
Sort By:
Page
of 4
Journal of Pharmacokinetics and Pharmacodynamics
|
November 6, 2017
Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection
Yasunori Aoki, Daniel Röshammar, Bengt Hamrén, et al.
British Journal of Clinical Pharmacology
|
July 25, 2016
Application of the integrated glucose-insulin model for cross-study characterization of T2DM patients on metformin background treatment
Joanna Parkinson, Bengt Hamrén, Maria C Kjellsson, et al.
British Journal of Clinical Pharmacology
|
February 26, 2008
Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion
Bengt Hamrén, Hans Ericsson, Ola Samuelsson, et al.
Journal of Clinical Pharmacology
|
May 21, 2010
A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes
Jakob Ribbing, Bengt Hamrén, Maria K Svensson, et al.
Clinical Pharmacokinetics
|
April 12, 2019
Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease
Carl Amilon, Mohammad Niazi, Anders Berggren, et al.
Pharmaceutical Research
|
August 2, 2020
Dose-Response Mixed Models for Repeated Measures - a New Method for Assessment of Dose-Response
Gustaf J Wellhagen, Bengt Hamrén, Maria C Kjellsson, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
February 1, 2017
Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
Daniel Röshammar, Martin Bergstrand, Tomas Andersson, et al.
Journal of Clinical Pharmacology
|
November 3, 2011
Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus
Bengt Hamrén, K Peter Ohman, Maria K Svensson, et al.
Journal of Clinical Pharmacology
|
November 19, 2016
Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction
Daniel Röshammar, Joakim Nyberg, Tomas Andersson, et al.
Journal of Clinical Pharmacology
|
October 4, 2014
Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA)
John Maringwa, Matts Kågedal, Ulrika Wählby Hamrén, et al.
Page
of 4